Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia

Blood

Volumn 114, Issue 18, 2009, Pages 3793-3802

  Zhou, Qing ^a   Bucher, Christoph ^a   Munger, Meghan E ^a   Highfill, Steven L ^a   Tolar, Jakub ^a   Munn, David H ^b   Levine, Bruce L ^c   Riddle, Megan ^a   June, Carl H ^c   Vallera, Daniel A ^d   Weigel, Brenda J ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; DENILEUKIN DIFTITOX; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DIPHTHERIA TOXIN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2-DIPHTHERIA TOXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MOUSE MUTANT; TRANSPLANTATION; TUMOR ESCAPE;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 70449723156     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-208181     Document Type: Article

References (56)

1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
3. Tallman MS, Dewald GW, Gandham S, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1):409-417.
4. Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother. 2007;56(7):943-957.
5. Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant. 2004;34(11):923-928.
6. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 2005;19(6):289-300.
7. Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008;21(3):455-466.
8. Loren AW, Porter DL. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol. 2006;18(2):107-114.
9. Cheuk AT, Chan L, Czepulkowski B, et al. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother. 2006;55(1):68-75.
10. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ. 2008;15(1):70-79.
11. Shankaran V, Ikeda H, Bruce AT, et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107-1111.
12. Finn OJ. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol Res. 2006;36(1-3):73-82.
13. Liakou CI, Narayanan S, Ng TD, Logothetis CJ, Sharma P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007;7:10.
14. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31(8):742-751.
15. Marijt E, Wafelman A, van der HM, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 2007;92(1):72-80.
16. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94(4):1201-1208.
17. Ghosh A, Wolenski M, Klein C, et al. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion. J Immunother. 2008;31(2):121-131.
18. Sauer MG, Ericson ME, Weigel BJ, et al. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res. 2004;64(11):3914- 3921.
19. Stone RM, DeAngelo DJ, Janosova A, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008;83(10):771-777.
20. Dohnal AM, Witt V, Hugel H, et al. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007;9(8):755-770.
21. Potebnya GP, Kudryavets YY, Lisovenko GS, et al. Experimental study of the efficacy of combined use of cancer vaccine and interferon. Exp Oncol. 2007;29(2):102-105.
22. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14(24):8270-8278.
23. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581-1588.
24. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest. 2004;114(10):1398-1403.
25. Zhang W, Liang S, Wu J, Horuzsko A. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation. 2008;86(8):1125-1134.
26. Dao Nguyen X, Robinson DS. Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism. J Allergy Clin Immunol. 2004;114(2):296-301.
27. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest. 2004;114(10):1389-1397.
28. Chen G, Hao J, Xi Y, et al. The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+CD25+ T regulatory cells. Scand J Immunol. 2008;68(6):572-578.
29. Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM. Cutting edge: antigen-specific TGFbeta-induced regulatory T cells suppress Th17-mediated autoimmune disease. J Immunol. 2008;181(12):8209-8213.
30. Wang X, Zheng J, Liu J, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;75(6):468-476.
31. Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of. Blood. 2007;109(7):2871-2877.
32. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328-2339.
33. Larmonier N, Marron M, Zeng Y, et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2007;56(1):48-59.
34. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205(10):2221-2234.
35. Grauer OM, Sutmuller RP, van Maren W, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2008;122(8):1794-1802.
36. Quezada SA, Peggs KS, Simpson TR, et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008;205(9):2125-2138.
37. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol. 2007;178(11):6840-6848.
38. Taylor PA, Ehrhardt MJ, Lees CJ, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood. 2007;110(9):3480-3488.
39. Weigel BJ, Panoskaltsis-Mortari A, Diers M, et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006;34(10):1403-1412.
40. Hoves S, Krause SW, Scholmerich J, Fleck M. The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis. Methods. 2003;31(2):127-134.
41. Chan CH, Blazar BR, Eide CR, Kreitman RJ, Vallera DA. A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. Blood. 1995;86(7):2732-2740.
42. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186-192.
43. Bignone PA, Banham AH. FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther. 2008;8(12):1897-1920.
44. Robertson SJ, Messer RJ, Carmody AB, Hasenkrug KJ. In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. J Immunol. 2006;176(6):3342-3349.
45. Litzinger MT, Fernando R, Curiel TJ, et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192-3201.
46. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15(10):3325-3332.
47. Pandolfi F, Cianci R, Lolli S, et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol. 2008;21(3):493-500.
48. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloidderived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13(18 pt 1):5243-5248.
49. Powell DJ Jr, Attia P, Ghetie V, et al. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother. 2008;31(2):189-198.
50. Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179(7):4919-4928.
51. Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007;120(12):2723-2733.
52. Imai H, Saio M, Nonaka K, et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. 2007;98(3):416-423.
53. Hallett WH, Ames E, Alvarez M, et al. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant. 2008; 14(10):1088-1099.
54. Seo N, Yamashiro H, Tadaki T. Anti-infective and anti-tumor agents based on the depletion of immune suppressive effects. Curr Med Chem. 2008;15(10):991-996.
55. Watanabe S, Deguchi K, Zheng R, et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008;181(5):3291-3300.
56. Stemberger C, Huster KM, Koffler M, et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity. 2007;27(6):985-997.